Search - tctmd.com

Presenter: Hirotoshi Watanabe, Kyohei Yamaji, Yoshimitsu Soga, Shinichi Shirai, Kenji Ando, Koyu Sakai, Katsuhiro Kondo, Masashi Iwabuchi, Hiroyoshi Yokoi, Hideyuki Nosaka, Masakiyo Nobuyoshi

January 03, 2012

Advertisement

Stent Thrombosis Risk Lower with Xience vs. First-Generation DES

Restenotic Pattern After Femoropopliteal Stenting Predicts Recurrence

El Riesgo de Trombosis del Stent es Menor con Xience que con SLF de 1ª Generación

El Patrón Re-estenótico tras Colocación de Stent Femoropoplíteo Predice la Recurrencia

El Estudio no Halla “Paradoja de la Obesidad” alguna en Pacientes Tratados con SLF

PEPCAD-DES: Paclitaxel-Coated Balloon Bests Plain Balloon for DES Restenosis

Meta-Analysis: Mixed Results Seen with First-Gen DES in STEMI Patients

Meta Análisis: Resultados Contradictorios con los SLF de 1ª Generación en Pacientes STEMI

El Estudio PEPCAD-DES: El Balón recubierto de Paclitaxel es mejor que el Balón convencional para resolver la reestenosis de un SLF

Boston Scientific Announces Launch of PROMUS Element™ Platinum Chromium Stent System in Japan

Estudio prospectivo multicentro comparativo entre la angioplastia con globo de paclitaxel y globo convencional contra la reestenosis de SLF

A Prospective Multicenter Trial Comparing Paclitaxel-Coated Balloon Angioplasty with Uncoated Balloon Angioplasty in DES Restenosis

Boston Scientific Receives Industry's First FDA Approval for Drug-Eluting Coronary Stent Use in Heart Attack Patients

Complications of In-Stent Restenosis High, Traditional Risk Factors Absent

Eurocor GmbH announces presentation of Valentines Trial II results at CRT2012

NEXT Up: Polymer-Free SES Angiographically Superior to Taxus

Eurocor announces treatment of First Patients in International Randomized Freeride Study

Ensayo Aleatorizado Multicentro Comparador de Amfilimus con Stents Liberadores de Paclitaxel en Lesiones Coronarias Nativas De Novo

A Multicenter Randomized Trial Comparing Amphilimus- With Paclitaxel-Eluting Stents in De Novo Native Coronary Artery Lesions

Use Of Paclitaxel-Eluting Stents Reduces Target Lesion Revascularization for Dialysis Patients.

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content